IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to halt kidney damage in IgA nephropathy
Disease control OngoingThis large, late-stage study is testing whether an investigational drug called povetacicept can help adults with IgA nephropathy, a serious kidney disease. The main goals are to reduce protein in the urine and slow the decline of kidney function over two years. Researchers will c…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial targets root cause of multiple serious kidney diseases
Disease control OngoingThis study is testing a new drug called povetacicept in adults with several serious autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The main goals are to see if the drug is safe and if it can help control these diseases. Participants receive injections …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug trial aims to slow kidney damage in IgA nephropathy patients
Disease control OngoingThis study is testing whether the drug BION-1301 can help adults with IgA nephropathy, a kidney disease that can lead to kidney failure. About 383 participants will receive either the drug or a placebo injection every two weeks for two years. The main goal is to see if the drug r…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New shot aims to slow silent kidney killer
Disease control OngoingThis large, late-stage study is testing whether a new injectable drug called sibeprenlimab can help people with IgA nephropathy, an autoimmune kidney disease. About 530 adults with confirmed disease will receive either the drug or a placebo shot every 4 weeks for up to 2 years. T…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC